Home › Funds › ISTHMUS PARTNERS, LLC › LGND
ISTHMUS PARTNERS, LLC position in LGND
LIGAND PHARMACEUTICALS INC · Health Care
ISTHMUS PARTNERS, LLC reported holding 20,935 shares of LGND (LIGAND PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$6.6M, representing 0.64% of its reported portfolio and ranking #49 among its reported holdings. ISTHMUS PARTNERS, LLC has disclosed LGND holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ISTHMUS PARTNERS, LLC's LGND position evolved
ISTHMUS PARTNERS, LLC first disclosed a stake in LGND in Q1 2026 at 24,059 shares (US$4.8M). The position peaked in Q2 2026 at 20,935 shares, worth US$6.6M. Across 2 filings, ISTHMUS PARTNERS, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 20,935 shares valued at US$6.6M — a reduction of -3,124 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 24.06K | $4.80M | New |
| Q2 2026 | 20.93K | $6.62M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LGND and 13F data
LGND (LIGAND PHARMACEUTICALS INC) is a Health Care company. 58 other funds we track also report a position in LGND — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$205.7M), Chicago Capital, LLC (US$172.2M), Stephens Investment Management Group LLC (US$150.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LGND
- CONGRESS ASSET MANAGEMENT CO 658.56K sh · $205.71M · Q3 2026
- Chicago Capital, LLC 551.23K sh · $172.19M · Q3 2026
- Stephens Investment Management Group LLC 475.61K sh · $150.34M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 270.05K sh · $85.36M · Q2 2026
- Ranger Investment Management, L.P. 257.60K sh · $81.42M · Q2 2026
- GW&K Investment Management, LLC 246.88K sh · $78.04M · Q2 2026
- NEXT CENTURY GROWTH INVESTORS LLC 198.54K sh · $62.76M · Q2 2026
- ASHFORD CAPITAL MANAGEMENT INC 170.24K sh · $53.81M · Q2 2026
- Private Capital Management, LLC 166.02K sh · $52.48M · Q2 2026
- VILLERE ST DENIS J & CO LLC 155.51K sh · $49.15M · Q2 2026
- Granahan Investment Management, LLC 147.23K sh · $46.54M · Q2 2026
- Penn Capital Management Company, LLC 100.34K sh · $31.75M · Q2 2026
More on ISTHMUS PARTNERS, LLC
FAQ
How long has ISTHMUS PARTNERS, LLC held LGND?
ISTHMUS PARTNERS, LLC has disclosed LGND holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is ISTHMUS PARTNERS, LLC's current position in LGND?
As of Q2 2026, ISTHMUS PARTNERS, LLC holds 20.93K shares of LGND (LIGAND PHARMACEUTICALS INC), valued at $6.62M, representing 0.64% of its reported portfolio and ranking #49.
Has ISTHMUS PARTNERS, LLC been buying or selling LGND?
In the latest 13F filing (Q2 2026), ISTHMUS PARTNERS, LLC reduced its position in LGND. The position peaked in Q2 2026 at 20.93K shares.
Which other funds hold LGND?
Other major institutional holders of LGND include CONGRESS ASSET MANAGEMENT CO, Chicago Capital, LLC, Stephens Investment Management Group LLC, among 58 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.